Please assess the completion status of the following clinical trial:

Trial Title: A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (HIV negative patients):~1. Has signed an informed consent~2. Aged 18 to 65 years~3. Has been diagnosed with active TB:~   1. has a compatible clinical picture of TB according to South African guidelines with the intention to treat and at least 1 documented positive sputum smear microscopy result or~  2. has a compatible clinical picture of TB according to South African Guidelines with the intention to treat and a positive culture result~4. Is HIV negative confirmed by 2 two rapid tests (Abbott-DetermineTM HIV-1/2 and Sensa (Seyama Solutions, SA))~5. Is willing and likely to comply with the trial procedures~6. Is prepared to grant authorized persons access to their medical record~Inclusion Criteria (HIV positive patients):~1. Has signed an informed consent~2. Aged 18 to 65 years~3. Has a compatible clinical picture of TB according to South African guidelines with the intention to treat~4. Is HIV positive confirmed by:~   1. 2 positive rapid tests (Abbott-DetermineTM HIV-1/2 and Sensa (Seyama Solutions, SA)) or~  2. 1 positive rapid tests (Abbott-DetermineTM HIV-1/2 or Sensa (Seyama Solutions, SA)) and an additional confirmatory ELISA (Enzygnost anti-HIV-1/2 Plus)~5. Is willing and likely to comply with the trial procedures~6. Is prepared to grant authorized persons access to their medical records~Exclusion Criteria:~1. Has been in treatment for TB for more than 2 weeks~2. Has a known MDR/XDR-TB~3. Has within 3 months prior to the day of inclusion been in treatment with a product which is likely to modify the immune response except for HIV treatment (e.g., immunoglobulin, systemic corticosteroids, methotrexate, azathioprine, cyclosporine or blood products)~4. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines)~5. Has been vaccinated with BCG \< 6 months prior to the day of inclusion~6. Has been tuberculin (TST) tested \< 6 months prior to the day of inclusion~7. Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~8. Has a current skin condition which interferes with the reading of the skin tests e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~9. Has a condition where blood drawings pose more than minimal risk for the patient, such as haemophilia, other coagulation disorders, or significantly impaired venous access~10. Currently participating in another clinical trial with an investigational or non investigational drug or device, or has participated in another clinical trial within the 3 months prior to dosing~11. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens~12. Is pregnant, breastfeeding or intending to get pregnant~13. Has a condition which in the opinion of the investigator is not suitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.1 µg/0.1 mL C-Tb (Type: EXPERIMENTAL): The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
- 2 TU Tuberculin PPD RT 23 SSI (Type: ACTIVE_COMPARATOR): The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme

Based on this trial design, predict the completion outcome and termination type (if applicable).